Novartis in-licenses WT1 mAb

Eureka Therapeutics Inc. (Emeryville, Calif.) and Memorial Sloan Kettering Cancer Center granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to develop and commercialize ESK1, a preclinical mAb against Wilm's Tumor 1 ( WT1) in development for cancer. Eureka and the center will receive an undisclosed upfront payment, and are eligible for undisclosed milestones and royalties. ...